var data={"title":"Ibrutinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ibrutinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/704630?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ibrutinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ibrutinib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22769660\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Imbruvica</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26597076\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Imbruvica</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22688543\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent;</li>\n      <li>\n        Antineoplastic Agent, Bruton Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802477\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic graft-versus-host disease (cGVHD; refractory): </b>Oral: 420 mg once daily; continue until cGVHD disease progression, recurrence of underlying malignancy, or unacceptable toxicity (Miklos 2016). When cGVHD treatment is no longer required, discontinue ibrutinib based on medical assessment of patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL):</b> Oral: 420 mg once daily (either as monotherapy or in combination with bendamustine and rituximab); continue until disease progression or unacceptable toxicity (Byrd 2014; Chanan-Khan 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CLL/SLL with 17p deletion:</b> Oral: 420 mg once daily; continue until disease progression or unacceptable toxicity (Byrd 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma (MCL), previously treated:</b> Oral: 560 mg once daily; continue until disease progression or unacceptable toxicity (Wang 2013; Wang 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Marginal zone lymphoma (MZL), relapsed/refractory: Oral: </b>560 mg once daily; continue until disease progression or unacceptable toxicity (Noy 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Waldenstr&ouml;m macroglobulinemia (WM):</b> Oral: 420 mg once daily; continue until disease progression or unacceptable toxicity (Treon 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> Administer as soon as the missed dose is remembered on the same day; return to normal scheduling the following day. Do not take extra capsules to make up for the missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Resume previous ibrutinib dose after discontinuation of the CYP3A inhibitor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>B-cell malignancies:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate CYP3A inhibitors, voriconazole 200 mg twice daily, posaconazole suspension 100 mg once daily, 100 mg twice daily, or 200 mg twice daily: </i>Reduce ibrutinib dose to 140 mg once daily. Monitor closely and interrupt ibrutinib treatment as recommended for toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Posaconazole suspension 200 mg three times daily or 400 mg twice daily, posaconazole 300 mg IV once daily, or posaconazole delayed-release tablets 300 mg once daily: </i>Reduce ibrutinib dose to 70 mg once daily. Monitor closely and interrupt ibrutinib treatment as recommended for toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other strong CYP3A inhibitors: </i>Avoid concurrent use. If these inhibitors will be used short-term (eg, anti-infectives for &le;7 days), interrupt ibrutinib treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>cGVHD:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate CYP3A inhibitors:</i> Administer ibrutinib at 420 mg once daily. Monitor closely and interrupt ibrutinib treatment as recommended for toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Voriconazole 200 mg twice daily, posaconazole suspension 100 mg once daily, 100 mg twice daily, or 200 mg twice daily: </i>Reduce ibrutinib dose to 280 mg once daily. Monitor closely and interrupt ibrutinib treatment as recommended for toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Posaconazole suspension 200 mg three times daily or 400 mg twice daily, posaconazole 300 mg IV once daily, or posaconazole delayed-release tablets 300 mg once daily: </i>Reduce ibrutinib dose to 140 mg once daily. Monitor closely and interrupt ibrutinib treatment as recommended for toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other strong CYP3A inhibitors: </i>Avoid concurrent use. If these inhibitors will be used short-term (eg, anti-infectives for &le;7 days), interrupt ibrutinib treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802478\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802479\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;25 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, renal excretion is minimal and drug exposure is not altered in patients with mild to moderate impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;25 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD) requiring dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802480\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): Reduce dose to 140 mg once daily. Monitor closely for toxicities; may require treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (Child-Pugh class B): Reduce dose to 70 mg once daily. Monitor closely for toxicities; may require treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802481\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic toxicity:</b> &ge; Grade 3 neutropenia with infection or fever, or grade 4 toxicity: Interrupt therapy; upon improvement to grade 1 toxicity or baseline, resume dosing at the starting dose. If toxicity recurs, reduce daily dose by 140 mg. If toxicity recurs after first dose reduction, reduce daily dose by an additional 140 mg. If toxicity persists following 2 dose reductions, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonhematologic toxicity:</b> &ge; Grade 3 toxicity: Interrupt therapy; upon improvement to grade 1 toxicity or baseline, resume dosing at the starting dose. If toxicity recurs, reduce daily dose by 140 mg. If toxicity recurs after first dose reduction, reduce daily dose by an additional 140 mg. If toxicity persists following 2 dose reductions, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Recommend dose reductions for toxicity (following recovery):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic graft-versus-host disease,<b>and</b> Waldenstr&ouml;m macroglobulinemia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First occurrence: Restart at 420 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second occurrence: Restart at 280 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third occurrence: Restart at 140 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fourth occurrence: Discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mantle cell lymphoma <b>and</b> marginal zone lymphoma:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First occurrence: Restart at 560 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second occurrence: Restart at 420 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third occurrence: Restart at 280 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fourth occurrence: Discontinue</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22769661\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imbruvica: 70 mg, 140 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imbruvica: 140 mg, 280 mg, 420 mg, 560 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22769659\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51192559\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Imbruvica tablets: FDA approved February 2018; availability anticipated in March 2018. Imbruvica tablets will be available in 140 mg, 280 mg, 420 mg, and 560 mg presentations. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802484\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer orally with water at approximately the same time every day. Swallow capsules whole; do not open, break, or chew the capsules. Maintain adequate hydration during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Based on an analysis of 3 pharmacokinetic studies, it is suggested that ibrutinib may be administered without regard to food (de Jong 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib was administered via nasogastric (NG) and percutaneous endoscopic gastrostomy (PEG) tube (single case report) by opening the capsule contents and flushing the contents down the tube(s) with water (Maddox 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132631\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Ibrutinib may cause teratogenicity and has a structure/toxicity profile similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, if unable to swallow whole), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22688545\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic graft-versus-host disease (refractory): </b>Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia/small lymphocytic lymphoma:</b> Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); treatment of CLL/SLL in patients with 17p deletion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma, previously treated:</b> Treatment of mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Marginal zone lymphoma, relapsed/refractory: </b>Treatment of marginal zone lymphoma (MZL) in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Waldenstr&ouml;m macroglobulinemia:</b> Treatment of Waldenstr&ouml;m macroglobulinemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22797741\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ibrutinib may be confused with Ibrance, ibritumomab, idelalisib, imatinib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) included among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22806759\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (12% to 35%), hypertension (6% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (21% to 57%), dizziness (11% to 20%), headache (12% to 18%), anxiety (16%), chills (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (12% to 29%), skin infection (14% to 16%), pruritus (11% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperuricemia (15% to 16%), hypoalbuminemia (14%), hypokalemia (12% to 13%), dehydration (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (36% to 59%), nausea (20% to 31%), stomatitis (14% to 29%), constipation (12% to 25%), abdominal pain (14% to 24%), vomiting (11% to 23%), decreased appetite (16% to 21%), dyspepsia (11% to 19%), gastroesophageal reflux disease (13%), upper abdominal pain (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (10% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (33% to 69%; grades 3/4: 5% to 17%), neutropenia (22% to 53%; grades 3/4: 13% to 29%), bruise (12% to 51%; grades 3/4: &le;2%), decreased hemoglobin (13% to 43%; grades 3/4: &le;13%), hemorrhage (26% to 30%; grades &ge;3: &le;6%; &ge;grade 3 bleeding events include gastrointestinal bleeding, hematuria, postprocedural hemorrhage, intracranial hemorrhage, subdural hematoma), petechia (11% to 16%), malignant neoplasm (secondary; 3% to 16%; non-melanoma skin cancer was most frequently reported; also includes carcinoma and one case of histiocytic sarcoma)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (14% to 40%), muscle spasm (11% to 29%), arthralgia (11% to 24%), weakness (14%), arthropathy (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Dry eye syndrome (17%), increased lacrimation (13%), blurred vision (10% to 13%), decreased visual acuity (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (16% to 47%), dyspnea (12% to 27%), cough (13% to 22%), sinusitis (11% to 22%), pneumonia (11% to 21%), epistaxis (11% to 19%), oropharyngeal pain (14%), bronchitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (17% to 25%), falling (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation (&le;9%), atrial flutter (&le;9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (1.5 to 3 x ULN: 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal platelet aggregation (Kamel 2015), hepatic failure, hypersensitivity (includes anaphylactic shock, angioedema, urticaria), hyponatremia (Burger 2015), interstitial pulmonary disease, onychoclasis, pneumonia due to Pneumocystis carinii, pneumonitis (Mato 2016), progressive multifocal leukoencephalopathy, reactivation of HBV, renal failure, Stevens-Johnson syndrome, tumor lysis syndrome, ventricular tachycardia (Lampson 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22688546\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Known hypersensitivity to ibrutinib or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802161\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Serious (and some fatal) cardiac arrhythmias have occurred with therapy, including grade 3 or greater atrial fibrillation and flutter and grade 3 or greater ventricular tachyarrhythmias. Cardiac events have occurred particularly in patients with cardiac risk factors, hypertension, infections (acute), or with a history of arrhythmias. Monitor periodically for clinical symptoms of cardiac arrhythmias (eg, palpitations, light-headedness, syncope, chest pain); an ECG should be performed if symptoms or new-onset dyspnea develop. Manage arrhythmias appropriately; for persistent events, evaluate the risk-benefit of ibrutinib treatment and dose modification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness, fatigue, and/or weakness, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Diarrhea has been commonly observed; maintain adequate hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Grade 3 and 4 neutropenia, thrombocytopenia, and anemia occurred commonly during clinical studies in patients who received single-agent ibrutinib for B-cell malignancies. Monitor blood counts monthly or as clinically necessary. Lymphocytosis (&ge;50% increase from baseline) may occur upon therapy initiation, generally within the first few weeks of therapy. The increase in lymphocytes is temporary, and resolves by a median of 8 weeks (mantle cell lymphoma) or 14 weeks (chronic lymphocytic leukemia). Some patients who developed lymphocytosis (lymphocytes &gt;400,000/mcL) have developed intracranial hemorrhage, lethargy, headache, and gait instability (some cases may have been associated with disease progression). Monitor for leukostasis, particularly in patients experiencing a rapid increase in lymphocytes to &gt;400,000/mcL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Grade 3 or higher bleeding events (intracranial hemorrhage [including subdural hematoma], GI bleeding, hematuria, and postprocedural bleeding) have occurred; some events were fatal. Bleeding events of any grade, including bruising and petechiae have occurred in approximately half of patients receiving ibrutinib. Monitor for signs of bleeding. Patients receiving concurrent antiplatelet or anticoagulant treatment may have an increased risk for bleeding. Evaluate the risk-benefit of withholding ibrutinib for 3 to 7 days prior to and after surgery, depending on the procedure type and risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Hypertension has been reported with ibrutinib therapy. The median onset of hypertension was 4.6 months (range: 0.03 to 22 months). Monitor for new onset hypertension or hypertension that is not adequately controlled after treatment initiation. May require antihypertensive therapy or adjustment of existing antihypertensive regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Serious infections (some fatal) have been observed, including bacterial, viral, and fungal infections. Cases of <i>Pneumocystis jirovecii</i> pneumonia (PCP) have also been reported (Ahn 2016). Monitor and evaluate for fever and other signs/symptoms of infection and manage appropriately. Consider prophylaxis (according to standard of care) for patients at increased risk for opportunistic infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal encephalopathy: Progressive multifocal encephalopathy (PML) has been observed; evaluate for symptoms and manage appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Renal failure has been reported with use; some cases were fatal. Clinical trials report serum creatinine increases of up to 3 times ULN; monitor renal function periodically and maintain hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Second primary malignancies: Patients treated with ibrutinib have developed second primary malignancies, including skin cancers and other carcinomas. Evaluate for sign/symptoms of malignancy during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome has been reported (rare); increased uric acid levels have been observed, including grade 4 elevations. Assess risk for tumor lysis syndrome (eg, high tumor burden); monitor closely in patients at risk and manage appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Ibrutinib is hepatically metabolized, and exposure is increased in patients with hepatic dysfunction. Dosage adjustment is recommended in patients with mild or moderate (Child-Pugh class A or B) impairment; avoid use in patients with severe (Child-Pugh class C) impairment. Monitor closely for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: While ibrutinib is minimally excreted by the kidney and exposure is not affected in patients with mild to moderate impairment, renal failure has been observed in studies. Use with caution in patients with pre-existing renal impairment; has not been studied in those with severe impairment or in patients on dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Waldenstr&ouml;m macroglobulinemia: Hyperviscosity may require plasmapheresis prior to or during ibrutinib treatment in patients with Waldenstr&ouml;m macroglobulinemia; adjustment of ibrutinib dose due to plasmapheresis is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adherence: A retrospective analysis of a phase 3 efficacy trial in previously treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma evaluated the effect of dose intensity on progression-free survival (PFS) and overall response rate (ORR). A higher dose intensity was associated with longer median PFS and a higher ORR; optimal outcomes were achieved in patients with sustained adherence to a 420 mg/day dosing schedule (Barr 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22813084\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22813081\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91587&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Ibrutinib may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Ibrutinib may enhance the adverse/toxic effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bitter Orange: May increase the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clotrimazole (Oral): May increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Ibrutinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, decrease ibrutinib to 140 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ibrutinib. Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Ibrutinib may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: May increase the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flaxseed Oil: May enhance the antiplatelet effect of Ibrutinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Ibrutinib may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Ibrutinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Ibrutinib. Management: Ibrutinib dose reductions are required when combined with posaconazole. Dose recommendations depend on the indication for ibrutinib and the posaconazole dose. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofisopam: May increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Ibrutinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Ibrutinib. Management: Ibrutinib dose reductions are required when combined with voriconazole. Dose recommendations depend on the indication for ibrutinib and the voriconazole dose. See full monograph for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802463\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit and Seville oranges inhibit CYP3A (moderately or strongly) and may increase ibrutinib exposure. Management: Avoid grapefruit and Seville oranges during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22797744\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on animal reproduction studies, ibrutinib may cause fetal harm if administered during pregnancy. For women of reproductive potential, verify pregnancy status prior to treatment initiation. Women of reproductive potential should avoid pregnancy during therapy and for up to 1 month after treatment cessation; males should avoid fathering a child during treatment and for 1 month after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22797746\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ibrutinib is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the breastfeeding infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802483\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Avoid grapefruit, grapefruit juice, and Seville oranges during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802486\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor blood counts monthly or as clinically necessary; renal and hepatic function; uric acid levels as clinically necessary; verify pregnancy status prior to treatment initiation (in women of reproductive potential); sign/symptoms of bleeding, infections, progressive multifocal encephalopathy, tumor lysis syndrome, and second primary malignancies; signs/symptoms of cardiac arrhythmias; ECG prior to initiation (patients with cardiac risk factors or history of cardiac arrhythmias) and during therapy if clinically indicated. Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802465\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ibrutinib is a potent and irreversible inhibitor of Bruton's tyrosine kinase (BTK), an integral component of the B-cell receptor (BCR) and cytokine receptor pathways. Constitutive activation of B-cell receptor signaling is important for survival of malignant B-cells; BTK inhibition results in decreased malignant B-cell proliferation and survival.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22802467\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~10,000 L (Marostica 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Absolute bioavailability in fasted condition was 2.9% and doubled when combined with a meal. Administration with food increased the C<sub>max</sub> by ~2- to 4-fold and the AUC 2-fold (compared with overnight fasting). Administration under fasting conditions resulted in exposure of ~60% compared to when administered either 30 minutes before or after a meal, or 2 hours after a high-fat meal (de Jong 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~97%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A (major) and CYP2D6 (minor) to active metabolite PCI-45227</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1 to 2 hours (4 hours under fed conditions [de Jong 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (80%; 1% as unchanged drug); urine (&lt;10%, as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613369\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Imbruvica Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (28): $13,641.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg (90): $14,615.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imbruvica Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg (28): $13,641.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">280 mg (28): $13,641.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 mg (28): $13,641.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">560 mg (28): $13,641.49</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27529528\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Imbruvica (AU, BB, CH, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, JP, KR, LT, LU, LV, MT, MY, NI, NL, NO, PA, PL, PT, RO, SA, SE, SG, SI, SK, SV);</li>\n      <li>Imbruvixa (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. <i>J Clin Oncol</i>. 2013;31(1):88-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/23045577/pubmed\" target=\"_blank\" id=\"23045577\">23045577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. <i>Blood</i>. 2016;128(15):1940-1943.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/27503501/pubmed\" target=\"_blank\" id=\"27503501\">27503501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr PM, Brown JR, Hillmen O, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i>. 2017;129(19):2612-2615.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28373262/pubmed\" target=\"_blank\" id=\"28373262\">28373262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>N Engl J Med</i>. 2015;373(25):2425-2437.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26639149/pubmed\" target=\"_blank\" id=\"26639149\">26639149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <i>N Engl J Med</i>. 2014;371(3):213-223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/24881631/pubmed\" target=\"_blank\" id=\"24881631\">24881631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. <i>N Engl J Med</i>. 2013;369(1):32-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/23782158/pubmed\" target=\"_blank\" id=\"23782158\">23782158</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncol</i>. 2016;17(2):200-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26655421/pubmed\" target=\"_blank\" id=\"26655421\">26655421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dasmahapatra G, Patel H, Dent P, et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. <i>Br J Haematol</i>. 2013;161(1):43-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/23360303/pubmed\" target=\"_blank\" id=\"23360303\">23360303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. <i>Cancer Chemother Pharmacol</i>. 2015;75(5):907-916.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25724156/pubmed\" target=\"_blank\" id=\"25724156\">25724156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet</i>. 2016;387(10020):770-778.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26673811/pubmed\" target=\"_blank\" id=\"26673811\">26673811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imbruvica (ibrutinib) [prescribing information]. Sunnyvale, CA: Pharmacyclics; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imbruvica (ibrutinib) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25138588\"></a>Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. <i>Leukemia</i>. 2015;29(4):783-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25138588/pubmed\" target=\"_blank\" id=\"25138588\">25138588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28223277\"></a>Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i>. 2017;129(18):2581-2584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28223277/pubmed\" target=\"_blank\" id=\"28223277\">28223277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maddox JM, Majid M. Use of ibrutinib via nasogastric (NG) tube &amp; percutaneous endoscopic gastrostomy (PEG) tube. <i>Blood</i>. 2016;128(22):5371 [abstract from 2016 American Society of Hematology annual meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mato AR, Islam P, Daniel C, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. <i>Blood</i>. 2016;127(8):1064-1067.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26702066/pubmed\" target=\"_blank\" id=\"26702066\">26702066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. <i>Cancer Chemother Pharmacol</i>. 2015;75(1):111-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25381051/pubmed\" target=\"_blank\" id=\"25381051\">25381051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miklos D, Cutler CS, Arora M, et al. Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids. <i>Blood</i>. 2016;128(22):LBA-3 [abstract LBA-3 from 2016 American Society of Hematology annual meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i>. 2017;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28167659/pubmed\" target=\"_blank\" id=\"28167659\">28167659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treon SP, Tripsas CK, Meid K et al. Ibrutinib in previously treated Waldenstr&ouml;m's macroglobulinemia. <i>N Engl J Med</i>. 2015;372(15):1430-1440.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25853747/pubmed\" target=\"_blank\" id=\"25853747\">25853747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 6, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i>. 2015;126(6):739-745.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26059948/pubmed\" target=\"_blank\" id=\"26059948\">26059948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <i>N Engl J Med</i>, 2013;369(6):507-516.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/23782157/pubmed\" target=\"_blank\" id=\"23782157\">23782157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i>. 2014;123(12):1810-1817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/24415539/pubmed\" target=\"_blank\" id=\"24415539\">24415539</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91587 Version 131.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F22769660\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F26597076\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F22688543\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F22802477\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F22802478\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22802479\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22802480\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F22802481\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F22769661\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F22769659\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51192559\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22802484\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132631\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F22688545\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F22797741\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F22806759\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22688546\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F22802161\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F22813084\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F22813081\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F22802463\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F22797744\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F22797746\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F22802483\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22802486\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F22802465\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F22802467\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23613369\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27529528\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/91587|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ibrutinib-patient-drug-information\" class=\"drug drug_patient\">Ibrutinib: Patient drug information</a></li></ul></div></div>","javascript":null}